ABOUT AMGEN AMGEN MISSION

To serve patients
Amgen is committed to unlocking the potential of biology for patients suffering
from serious illnesses by discovering, developing, manufacturing and delivering AMGEN QUICK FACTS
innovative human therapeutics. This approach begins by using tools like Headquarters
Thousand Oaks, California
advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology. Staff
Approximately 22,000 worldwide
Our belief—and the core of our strategy—is that innovative, highly
Stock Listing
differentiated medicines that provide large clinical benefits in addressing NASDAQ: AMGN
serious diseases are medicines that will not only help patients, but also will help
reduce the social and economic burden of disease in society today. Chairman and CEO
Robert A. Bradway
Amgen focuses on areas of high unmet medical need and leverages its 2019 Financial Highlights
expertise to strive for solutions that improve health outcomes and dramatically Total revenue: $23.4 billion
improve people’s lives. A biotechnology innovator since 1980, Amgen has Product sales: $22.2 billion
grown to be one of the world’s leading independent biotechnology companies, Non-GAAP R&D expense: $4.0 billion
has reached millions of patients around the world and is developing a pipeline Address/Phone
of medicines with breakaway potential. One Amgen Center Drive
Thousand Oaks, CA 91320-1799
INNOVATIVE MEDICINES Main: (805) 447-1000
We have a presence in approximately 100 countries and regions worldwide and our innovative Investors: (805) 447-1060
medicines have reached millions of people in the fight against serious illnesses. We focus on six
therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology PRODUCTS
and inflammation. Our medicines typically address diseases for which there are limited Aimovig® (erenumab-aooe)
treatment options, or they are medicines that provide a viable option to what is otherwise AMGEVITA™ (adalimumab)
available. Aranesp® (darbepoetin alfa)
BLINCYTO® (blinatumomab)
TRANSFORMATIVE RESEARCH Corlanor® (ivabradine)
Understanding the fundamental biological mechanisms of disease is a defining feature of Enbrel® (etanercept)
Amgen’s discovery research efforts—and a major contributor to the development of Amgen’s EPOGEN® (epoetin alfa)
deep and broad pipeline of potential new medicines. Amgen’s “biology first” approach permits its EVENITY® (romosozumab-aqqg)
scientists to first explore the complex molecular pathways of disease before determining what IMLYGIC® (talimogene laherparepvec)
type of medicine, or modality, is most likely to deliver optimal efficacy and safety. With the KANJINTI™ (trastuzumab-anns)
advances in human genetics, Amgen continues to shed new light on the molecular roots of KYPROLIS® (carfilzomib)
MVASI™ (bevacizumab-awwb)
disease. Amgen subsidiary deCODE Genetics, a global leader in human genetics, is a powerful
Neulasta® (pegfilgrastim)
differentiator, greatly improving how we identify and validate human disease targets.
NEUPOGEN® (filgrastim)
WORLD-CLASS BIOMANUFACTURING Nplate® (romiplostim)
The treatment of millions of seriously ill patients worldwide depends on the safe and reliable Otezla® (apremilast)
Parsabiv® (etelcalcetide)
production of biologic medicines, which are administered by injection or intravenously. A
Prolia® (denosumab)
worldwide leader in biologics manufacturing, Amgen has an outstanding track record of reliably
Repatha® (evolocumab)
delivering high-quality medicines to patients who need them. Significant skill, experience, Sensipar®/Mimpara® (cinacalcet)
vigilance and commitment are critical to help ensure the quality of a biologic medicine each time Vectibix® (panitumumab)
a new batch is made. At Amgen, robust quality control and a reliable supply of medicines for XGEVA® (denosumab)
patients are every bit as important as scientific innovation.
Aimovig® is developed in collaboration with
Novartis
For information about our pipeline and therapies,
visit www.amgen.com.
Last updated February 13, 2020 l Page 1
SENIOR MANAGEMENT OUR HERITAGE
Robert A. Bradway Building on advances in recombinant DNA and molecular biology, Amgen is counted among the
Chairman and Chief Executive Officer early pioneers of biotechnology. Since 1980, Amgen scientists have been at work developing novel
Victoria H. Blatter therapies for patients with serious illnesses. Our scientists have characterized key biologic
SVP, U.S. Government Affairs processes that have led to the development of innovative, first-in-class therapies. We have helped
Judy Gawlik Brown shape the scientific world’s understanding of certain disease processes, and we have engineered
SVP, Corporate Affairs new types of therapeutic platforms. As a company, we could not have accomplished what we have
Tia Bush were it not for our deep commitment to building a culture that embraces science and innovation—a
SVP, Quality culture that continues to shape who we are today.
Raymond Deshaies
SVP, Global Research THE AMGEN FOUNDATION
Steven K. Galson The Amgen Foundation seeks to advance excellence in science education to inspire the next
SVP, Global Regulatory Affairs and Safety generation of innovators, and invest in strengthening communities where Amgen staff members live
Murdo Gordon and work. To date, the Foundation has donated nearly $300 million in grants to local, regional and
EVP, Global Commercial Operations international nonprofit organizations that impact society in inspiring and innovative ways. The
Jonathan Graham Amgen Foundation brings the excitement of discovery to the scientists of tomorrow through several
EVP, General Counsel and Secretary signature programs, including Amgen Scholars, Amgen Biotech Experience and Amgen Teach. For
Peter Griffith more information, visit www.AmgenInspires.com.
EVP and Chief Financial Officer
Lori Johnston REACHING PATIENTS WORLDWIDE
EVP, Human Resources
Amgen medicines help patients worldwide with facilities or subsidiaries in the following locations:
Corinne M. Le Goff
SVP, General Manager U.S. General In the United States
Medicine California (South San Francisco, Thousand Oaks)
Elliott M. Levy Florida (Tampa)
SVP, Global Development
Kentucky (Louisville)
Gilles Marrache
Massachusetts (Cambridge, Woburn)
SVP, Regional General Manager
Puerto Rico (Juncos)
David W. Meline
EVP Rhode Island (West Greenwich)
Jerry Murry
Washington, D.C.
SVP, Process Development Outside the United States
Mike Nohaile Algeria Estonia Korea Saudi Arabia
SVP, Strategy, Commercialization
Argentina Finland Latvia Singapore
and Innovation
Australia France Lebanon Slovakia
Cynthia M. Patton
SVP and Chief Compliance Officer Austria Germany Lithuania Slovenia
Arleen Paulino Belgium Greece Luxemburg South Africa
SVP, Manufacturing Brazil Hong Kong Mexico Spain
David A. Piacquad Bulgaria Hungary Morocco Sweden
SVP, Business Development Canada Iceland Netherlands Switzerland
Annalisa Pizzarello China India New Zealand Taiwan
SVP, Results Delivery Office Colombia Ireland Norway Thailand
David M. Reese Croatia Italy Poland Turkey
EVP, Research and Development
Czech Republic Israel Portugal United Arab Emirates
Esteban Santos
Denmark Japan Romania United Kingdom
EVP, Operations
Egypt Jordan Russia
Darryl Sleep
SVP, Global Medical and Investor Information
Chief Medical Officer This fact sheet is a summary of more detailed disclosure that can be found in Amgen’s filings with the U.S. Securities and Exchange Commission and its
Susan Sweeney press releases. This fact sheet contains forward-looking statements that involve significant risks and uncertainties, discussion of which can be found in
Amgen’s most recent Forms 10-K, 10-Q, and 8-K and on http://investors.amgen.com. The information in this fact sheet is given as of the date below,
SVP, Global Product Strategy and and Amgen does not undertake any obligation to update any information in this document.
Commercial Innovation
Ian Thompson
SVP, Regional General Manager
Michael Zahigian
SVP, Chief Information Officer

Last updated February 13, 2020 l Page 2